Elucidating the endogenous synovial fluid proteome and peptidome of inflammatory arthritis using label-free mass spectrometry.
Biomarkers
Inflammatory arthritis
Mass spectrometry
Peptidomics
Proteomics
Psoriatic arthritis
Rheumatoid arthritis
Synovial fluid
Journal
Clinical proteomics
ISSN: 1542-6416
Titre abrégé: Clin Proteomics
Pays: England
ID NLM: 101184586
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
02
2019
accepted:
24
05
2019
entrez:
5
6
2019
pubmed:
5
6
2019
medline:
5
6
2019
Statut:
epublish
Résumé
Inflammatory arthritis (IA) is an immunological disorder in which loss of immune tolerance to endogenous self-antigens perpetuates synovitis and eventual destruction of the underlying cartilage and bone. Pathological changes in the joint are expected to be represented by synovial fluid (SF) proteins and peptides. In the present study, a mass spectrometry-based approach was utilized for the identification of key protein and peptide mediators of IA. Age-matched SF samples from 10 rheumatoid arthritis patients, 10 psoriatic arthritis patients and 10 cadaveric controls were subjected to an integrated proteomic and peptidomic protocol using liquid chromatography tandem mass spectrometry. Significant differentially abundant proteins and peptides were identified between cohorts according to the results of a Mann-Whitney U test coupled to the Benjamini-Hochberg correction for multiple hypothesis testing. Fold change ratios were computed for each protein and peptide according to their log-transformed extracted ion current. Pathway analysis and antimicrobial peptide (AMP) prediction were conducted to clarify the pathophysiological relevance of identified proteins and peptides to IA. We determined that 144 proteins showed significant differential abundance between the IA and control SF proteomes, of which 11 protein candidates were selected for future follow-up studies. Similar analyses applied to our peptidomic data identified 15 peptide sequences, originating from 4 protein precursors, to have significant differential abundance in IA compared to the control SF peptidome. Pathway enrichment analysis of the IA SF peptidome along with AMP prediction suggests a possible mechanistic role of microbes in eliciting an immune response which drives the development of IA. The discovery-phase data generated herein has provided a basis for the identification of candidates with the greatest potential to serve as novel serum biomarkers specific to inflammatory arthritides. Moreover, these findings facilitate the understanding of possible disease mechanisms specific to each subtype.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammatory arthritis (IA) is an immunological disorder in which loss of immune tolerance to endogenous self-antigens perpetuates synovitis and eventual destruction of the underlying cartilage and bone. Pathological changes in the joint are expected to be represented by synovial fluid (SF) proteins and peptides. In the present study, a mass spectrometry-based approach was utilized for the identification of key protein and peptide mediators of IA.
METHODS
METHODS
Age-matched SF samples from 10 rheumatoid arthritis patients, 10 psoriatic arthritis patients and 10 cadaveric controls were subjected to an integrated proteomic and peptidomic protocol using liquid chromatography tandem mass spectrometry. Significant differentially abundant proteins and peptides were identified between cohorts according to the results of a Mann-Whitney U test coupled to the Benjamini-Hochberg correction for multiple hypothesis testing. Fold change ratios were computed for each protein and peptide according to their log-transformed extracted ion current. Pathway analysis and antimicrobial peptide (AMP) prediction were conducted to clarify the pathophysiological relevance of identified proteins and peptides to IA.
RESULTS
RESULTS
We determined that 144 proteins showed significant differential abundance between the IA and control SF proteomes, of which 11 protein candidates were selected for future follow-up studies. Similar analyses applied to our peptidomic data identified 15 peptide sequences, originating from 4 protein precursors, to have significant differential abundance in IA compared to the control SF peptidome. Pathway enrichment analysis of the IA SF peptidome along with AMP prediction suggests a possible mechanistic role of microbes in eliciting an immune response which drives the development of IA.
CONCLUSIONS
CONCLUSIONS
The discovery-phase data generated herein has provided a basis for the identification of candidates with the greatest potential to serve as novel serum biomarkers specific to inflammatory arthritides. Moreover, these findings facilitate the understanding of possible disease mechanisms specific to each subtype.
Identifiants
pubmed: 31160890
doi: 10.1186/s12014-019-9243-3
pii: 9243
pmc: PMC6542032
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing financial interest.
Références
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Arthritis Rheum. 2000 Mar;43(3):608-16
pubmed: 10728755
J Immunol. 2000 Nov 1;165(9):5255-61
pubmed: 11046059
J Pathol. 2002 Nov;198(3):369-77
pubmed: 12375270
J Immunol. 2003 Jan 15;170(2):838-45
pubmed: 12517948
Circulation. 2003 Mar 11;107(9):1303-7
pubmed: 12628952
Amino Acids. 2004 Dec;27(3-4):249-59
pubmed: 15592754
Clin Exp Immunol. 1992 May;88(2):313-7
pubmed: 1572097
Arthritis Res Ther. 2006;8(1):R5
pubmed: 16356189
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
J Proteome Res. 2006 Sep;5(9):2152-8
pubmed: 16944926
J Proteome Res. 2007 Feb;6(2):828-36
pubmed: 17269739
J Proteome Res. 2007 Nov;6(11):4388-96
pubmed: 17929855
Clin Chem. 2008 Oct;54(10):1608-16
pubmed: 18687737
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Immunol. 2010 Jan 1;184(1):379-90
pubmed: 19949094
Proteomics Clin Appl. 2007 Aug;1(8):889-99
pubmed: 21136742
Arthritis Rheum. 2011 Apr;63(4):884-93
pubmed: 21452313
Nat Rev Rheumatol. 2011 Jun 14;7(7):381-90
pubmed: 21670767
Nat Rev Rheumatol. 2011 Aug 23;7(10):569-78
pubmed: 21862983
Arthritis Rheum. 2012 Jan;64(1):141-52
pubmed: 21898359
Mol Cell Proteomics. 2012 Feb;11(2):M111.013904
pubmed: 21997733
Mol Cancer. 2013 Oct 07;12(1):117
pubmed: 24098938
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
J Immunol Res. 2014;2014:696415
pubmed: 24955375
Clin Proteomics. 2014 Jul 01;11(1):27
pubmed: 25097465
Arthritis Rheumatol. 2014 Dec;66(12):3300-10
pubmed: 25155522
Arthritis Rheumatol. 2015 Jan;67(1):128-39
pubmed: 25319745
Lupus. 2015 May;24(6):582-7
pubmed: 25391542
Curr Opin Rheumatol. 2015 Mar;27(2):118-26
pubmed: 25603040
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Clin Proteomics. 2015 Jan 13;12(1):1
pubmed: 25678896
Iran J Basic Med Sci. 2014 Sep;17(9):651-5
pubmed: 25691940
Nat Med. 2015 Aug;21(8):895-905
pubmed: 26214836
Nucleic Acids Res. 2016 Jan 4;44(D1):D1094-7
pubmed: 26467475
Semin Thromb Hemost. 2016 Jun;42(4):408-21
pubmed: 27056151
Cell Div. 2016 Apr 22;11:6
pubmed: 27110270
J Transl Med. 2016 Aug 04;14(1):233
pubmed: 27492386
N Engl J Med. 2017 Mar 9;376(10):957-970
pubmed: 28273019
Eur Heart J. 2018 Oct 14;39(39):3608-3614
pubmed: 28444172
Enzymes. 2017;42:27-64
pubmed: 29054270
Nucleic Acids Res. 2018 Jan 4;46(D1):D1271-D1281
pubmed: 29106664
Sci Rep. 2017 Nov 15;7(1):15613
pubmed: 29142301
Bioinformatics. 2018 May 1;34(9):1589-1590
pubmed: 29309527
Cell Physiol Biochem. 2018;47(1):266-278
pubmed: 29768263
Am J Med. 1978 Sep;65(3):430-6
pubmed: 309726
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Gastroenterology. 1987 Feb;92(2):329-37
pubmed: 3792769
Br J Rheumatol. 1994 Nov;33(11):1030-8
pubmed: 7981990
Clin Cardiol. 1993 Jul;16(7):548-52
pubmed: 8348763
Nat Genet. 1997 Jul;16(3):311-5
pubmed: 9207801
Arthritis Rheum. 1997 Nov;40(11):1955-61
pubmed: 9365083